Jacobi Capital Management LLC raised its holdings in Novartis AG (NYSE:NVS – Get Rating) by 7.1% during the first quarter, Holdings Channel.com reports. The fund owned 5,429 shares of the company’s stock after purchasing an additional 359 shares during the period. Jacobi Capital Management LLC’s holdings in Novartis were worth $476,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. AHL Investment Management Inc. bought a new position in Novartis in the fourth quarter valued at approximately $25,000. Dixon Hughes Goodman Wealth Advisors LLC bought a new position in Novartis in the fourth quarter valued at approximately $32,000. Atwood & Palmer Inc. boosted its stake in Novartis by 400.0% in the first quarter. Atwood & Palmer Inc. now owns 375 shares of the company’s stock valued at $33,000 after acquiring an additional 300 shares during the last quarter. Allegheny Financial Group LTD bought a new position in Novartis in the fourth quarter valued at approximately $34,000. Finally, DeDora Capital Inc. bought a new position in Novartis in the first quarter valued at approximately $34,000. 9.40% of the stock is owned by institutional investors.
Novartis Trading Up 0.4 %
Shares of NYSE:NVS opened at $85.57 on Friday. Novartis AG has a 12 month low of $79.09 and a 12 month high of $95.17. The company has a quick ratio of 1.13, a current ratio of 1.38 and a debt-to-equity ratio of 0.35. The company’s fifty day simple moving average is $85.04 and its 200 day simple moving average is $86.61. The firm has a market cap of $189.33 billion, a price-to-earnings ratio of 8.36, a PEG ratio of 2.41 and a beta of 0.51.
Wall Street Analysts Forecast Growth
A number of equities analysts have issued reports on the stock. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Novartis from CHF 80 to CHF 75 in a research note on Wednesday, June 29th. Barclays lifted their price target on shares of Novartis from CHF 80 to CHF 85 in a research report on Thursday, April 14th. raised shares of Novartis from a “hold” rating to a “buy” rating in a research report on Thursday, April 14th. Credit Suisse Group lifted their price target on shares of Novartis from CHF 85 to CHF 88 in a research report on Thursday, April 28th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Novartis from CHF 80 to CHF 81 and gave the stock an “underweight” rating in a research report on Wednesday, July 20th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, Novartis currently has a consensus rating of “Hold” and an average price target of $87.33.
Novartis Company Profile
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products.
- Get a free copy of the StockNews.com research report on Novartis (NVS)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.